Literature DB >> 3950720

The occurrence of dural invasion in pituitary adenomas.

W R Selman, E R Laws, B W Scheithauer, S M Carpenter.   

Abstract

This report describes 60 dural specimens from patients with pituitary adenomas treated by transsphenoidal microsurgery, and attempts to define more precisely the clinical and pathological correlation of microscopic dural invasion. Analysis of the adenomas was based on four characteristics; size, surgical invasiveness (based on the surgeon's assessment of involvement by tumor of bone, dura, or cavernous sinus), histological evidence of invasion, and immunohistochemical staining characteristics. The incidence of surgical invasiveness (24 cases, 40%) was greater than previously reported, but most important was the frequent occurrence of microscopic dural invasion (51 cases, 85%). There was a clear progression of microscopic evidence of dural invasion with increasing tumor size: 69%, 88%, and 94% of the dural specimens from microadenomas, macroadenomas, and tumors with suprasellar extension, respectively, showed microscopic dural invasion. A correlation of invasiveness with immunohistochemical classification of tumor type was not evident.

Entities:  

Mesh:

Year:  1986        PMID: 3950720     DOI: 10.3171/jns.1986.64.3.0402

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  62 in total

Review 1.  Malignant pituitary tumours.

Authors:  G A Kaltsas; A B Grossman
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

2.  Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts.

Authors:  M Shibuya; F Saito; T Miwa; R L Davis; C B Wilson; T Hoshino
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

3.  Integrative proteomics and transcriptomics identify novel invasive-related biomarkers of non-functioning pituitary adenomas.

Authors:  Sheng-Yuan Yu; Li-Chuan Hong; Jie Feng; You-Tu Wu; Ya-Zhuo Zhang
Journal:  Tumour Biol       Date:  2016-01-11

4.  Role of transsphenoidal operation in the management of pituitary adenomas with suprasellar extension.

Authors:  O Bynke; J Hillman
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

5.  DNA-flow cytometry of 207 pituitary adenomas: ploidy, proliferation, and prognosis.

Authors:  A L O Machado; P Nomikos; F Kiesewetter; R Fahlbusch; M Buchfelder
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

6.  Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas.

Authors:  Jian Gong; Yunge Zhao; Rana Abdel-Fattah; Samson Amos; Aizhen Xiao; M Beatriz S Lopes; Isa M Hussaini; Edward R Laws
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 7.  Intracranial dissemination of pituitary adenoma. Case report and review of the literature.

Authors:  M T Giordana; P Cavalla; A Allegranza; B Pollo
Journal:  Ital J Neurol Sci       Date:  1994-05

8.  Invasive adenoma and pituitary carcinoma: a SEER database analysis.

Authors:  Tara M Hansen; Sachin Batra; Michael Lim; Gary L Gallia; Peter C Burger; Roberto Salvatori; Gary Wand; Alfredo Quinones-Hinojosa; Lawrence Kleinberg; Kristin J Redmond
Journal:  Neurosurg Rev       Date:  2014-02-14       Impact factor: 3.042

9.  Peel-off resection of the pituitary gland for functional pituitary adenomas: pathological significance and impact on pituitary function.

Authors:  Yuichi Nagata; Kazuhito Takeuchi; Taiki Yamamoto; Takayuki Ishikawa; Teppei Kawabata; Yoshie Shimoyama; Naoko Inoshita; Toshihiko Wakabayashi
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

Review 10.  Applications of radiotherapy and radiosurgery in the management of pediatric Cushing's disease: a review of the literature and our experience.

Authors:  Jay Jagannathan; Adam S Kanter; Claire Olson; Jonathan H Sherman; Edward R Laws; Jason P Sheehan
Journal:  J Neurooncol       Date:  2008-06-21       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.